Evusheld for the Treatment of Mild to Moderate COVID-19

( Last Updated : October 26, 2022)
Project Status:
Project Line:
Health Technology Review
Project Sub Line:
Technology Review
Project Number:
Effective finish date:


Tixagevimab and cilgavimab (Evusheld) is a combination of long-acting monoclonal antibodies for intramuscular administration for the treatment of mild to moderate COVID-19. CADTH conducted a review of the evidence and convened an Implementation Advice Panel to prioritize the patient populations that are most likely to benefit from treatment with Evusheld.